PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
and Japan; Xeljanz globally, up 18% operationally, primarily driven by: 16% growth in the U.S., First-quarter 2021 operational growth was primarily driven by: BNT162b2, which contributed $3.5 billion in global revenues; Eliquis globally, up 25% operationally, led by growth in the U.S., in December 2019; and. Amy Rose 212.733.7410.
40 
Let's personalize your content